Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

NCT02247401 PHASE3 COMPLETED Results posted

This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment-naive and treatment-experienced HCV GT4 subjects without or with compensated cirrhosis.

Details

Lead sponsor	AbbVie
Phase	PHASE3
Status	COMPLETED
Enrolment	160
Start date	Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Aug 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• HCV
• Hepatitis C Infection
• Genotype 4

Interventions

• 2 DAA
• RBV